Galanin System in Human Glioma and Pituitary Adenoma
Open Access
- 24 March 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 11, 155
Abstract
Expression of neuropeptides and their corresponding receptors has been demonstrated in different cancer types, where they can play a role in tumor cell growth, invasion and migration. Human galanin (GAL) is a 30-amino-acid regulatory neuropeptide which acts through three G protein-coupled receptors, GAL1-R, GAL2-R and GAL3-R that differ in their signal transduction pathways. GAL and galanin receptors (GALRs) are expressed by different tumors, and direct involvement of GAL in tumorigenesis has been shown. Despite its strong expression in the central nervous system (CNS), the role of GAL in CNS tumors has not been extensively studied. To date, GAL peptide expression, GAL receptor binding and mRNA expression have been reported in glioma, meningioma and pituitary adenoma. However, data on the cellular distribution of GALRs are sparse. The aim of the present study was to examine the expression of GAL and GALRs in different brain tumors by immunohistochemistry. Anterior pituitary gland (n=7), pituitary adenoma (n=9) and glioma of different WHO grades I-IV (n=55) were analyzed for the expression of GAL and the three GALRs with antibodies recently extensively validated for specificity. While high focal GAL immunoreactivity was detected in up to 40% of cells in the anterior pituitary gland samples, only one pituitary adenoma showed focal GAL expression, at a low level. In the anterior pituitary, GAL1-R and GAL3-R protein expression was observed in up to 15% of cells, whereas receptor expression was not detected in pituitary adenoma. In glioma, diffuse and focal GAL staining was noticed in the majority of cases. GAL1-R was observed in eight out of nine glioma subtypes. GAL2-R immunoreactivity was not detected in glioma and pituitary adenoma, while GAL3-R expression was significantly associated to high-grade glioma (WHO grade IV). Most interestingly, expression of GAL and GALRs was observed in tumor-infiltrating immune cells, including neutrophils and glioma-associated macrophages/microglia. The presence of GALRs on tumor-associated immune cells, especially macrophages, indicates that GAL signaling contributes to homeostasis of the tumor microenvironment. Thus, our data indicate that GAL signaling in tumor-supportive myeloid cells could be a novel therapeutic target.Keywords
Funding Information
- Paracelsus Medizinische Privatuniversität (E-16/24/124-KOB)
- Austrian Science Fund (P32403-3)
This publication has 56 references indexed in Scilit:
- Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal CancerClinical Cancer Research, 2012
- Galanin Receptor Subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer CellsClinical Cancer Research, 2009
- Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck CancerClinical Cancer Research, 2008
- Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2)Proceedings of the National Academy of Sciences, 2008
- Galanin Is Up-Regulated in Colon AdenocarcinomaCancer Epidemiology, Biomarkers & Prevention, 2007
- Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal DevelopmentCancer Research, 2005
- Expression of Neuropeptide Galanin and Galanin Receptors in Human SkinJournal of Investigative Dermatology, 2004
- Galanin down-regulates microglial tumor necrosis factor-α production by a post-transcriptional mechanismJournal of Neuroimmunology, 2003
- Galanin in human pituitary adenomas: frequency and clinical significanceClinical Endocrinology, 2002
- Galanin in the normal human pituitary and brain and in pituitary adenomasJournal of Endocrinology, 1991